CRNX: Crinetics Pharmaceuticals, Inc.
About
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Current Value
$55.331 Year Return
Current Value
$55.331 Year Return
Key Details
Market Cap
$5.12B
P/E Ratio
-14.84
1Y Stock Return
84.27%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
5.4
Strategies that include CRNX
Stock's related to CRNX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ARWR | 47.82% | $2.31B | -34.44% | 0.00% |
| ELVN | 44.92% | $1.28B | +135.01% | 0.00% |
| PGEN | 44.46% | $228.91M | -28.00% | 0.00% |
| RARE | 43.75% | $4.17B | +16.19% | 0.00% |
| ALEC | 42.82% | $377.04M | -19.46% | 0.00% |
| NTLA | 42.75% | $1.44B | -50.35% | 0.00% |
| EDIT | 41.81% | $204.72M | -75.49% | 0.00% |
| DNLI | 41.04% | $3.50B | +33.66% | 0.00% |
| KN | 39.99% | $1.60B | +12.19% | 0.00% |
| AXSM | 39.76% | $4.63B | +61.30% | 0.00% |
| MRSN | 39.68% | $274.24M | +40.51% | 0.00% |
| IDYA | 39.33% | $2.24B | -15.21% | 0.00% |
| AVXL | 39.03% | $698.71M | +22.62% | 0.00% |
| BBIO | 38.85% | $4.26B | -20.38% | 0.00% |
| ALDX | 38.71% | $294.18M | +102.46% | 0.00% |
| ARLO | 37.81% | $1.20B | +31.21% | 0.00% |
| RCKT | 37.34% | $1.20B | -39.83% | 0.00% |
| BEAM | 37.23% | $2.09B | -9.52% | 0.00% |
| ATXS | 37.15% | $550.23M | +114.29% | 0.00% |
| ATNM | 36.97% | $44.30M | -67.05% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NOC | 0.02% | $71.54B | +4.23% | 1.60% |
| VSTA | 0.07% | $204.94M | -39.33% | 0.00% |
| RSG | -0.08% | $66.05B | +31.79% | 1.04% |
| SOC | -0.11% | $1.93B | +74.70% | 0.00% |
| PGR | 0.13% | $149.10B | +57.29% | 0.45% |
| BVN | -0.20% | $3.16B | +37.49% | 0.00% |
| IMNN | -0.38% | $10.02M | -22.89% | 0.00% |
| CI | 0.39% | $89.70B | +12.57% | 1.68% |
| BACK | 0.41% | $1.76M | -32.90% | 0.00% |
| AIFU | 0.44% | $67.49M | -83.02% | 0.00% |
| AFL | -0.45% | $61.74B | +35.69% | 1.35% |
| ZI | 0.50% | $3.40B | -28.47% | 0.00% |
| CHD | -0.51% | $27.18B | +19.50% | 1.03% |
| NAPA | -0.51% | $1.63B | +9.61% | 0.00% |
| DV | 0.58% | $3.26B | -37.48% | 0.00% |
| SMR | -0.62% | $2.73B | +989.52% | 0.00% |
| CORZ | 0.65% | $4.60B | +3,201.26% | 0.00% |
| QXO | 0.68% | $6.51B | -35.95% | 0.00% |
| MGEE | 0.70% | $3.78B | +41.56% | 1.66% |
| LUMO | 0.74% | $37.45M | +41.97% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STG | -10.58% | $35.67M | +7.92% | 0.00% |
| XGN | -9.50% | $62.26M | +127.74% | 0.00% |
| QNTM | -8.77% | $9.19M | -94.36% | 0.00% |
| MNR | -7.22% | $1.66B | -10.71% | 15.90% |
| TTE | -6.85% | $138.45B | -11.95% | 5.50% |
| UUU | -6.41% | $4.97M | -41.89% | 0.00% |
| PULM | -6.35% | $19.83M | +202.98% | 0.00% |
| VZIO | -6.32% | $2.29B | +67.76% | 0.00% |
| CME | -6.21% | $82.76B | +9.21% | 1.98% |
| LTRN | -6.17% | $33.22M | -22.61% | 0.00% |
| WM | -5.67% | $87.92B | +27.58% | 1.34% |
| HUSA | -5.42% | $16.69M | -11.56% | 0.00% |
| SOLV | -5.25% | $11.58B | -16.19% | 0.00% |
| HRL | -5.21% | $16.30B | -8.38% | 3.81% |
| IMRN | -4.94% | $10.31M | -5.04% | 0.00% |
| COR | -4.82% | $47.48B | +21.20% | 0.86% |
| MNST | -4.69% | $52.25B | -1.95% | 0.00% |
| CMG | -4.08% | $80.02B | +33.62% | 0.00% |
| CMTL | -3.75% | $84.44M | -76.16% | 0.00% |
| GL | -3.13% | $9.18B | -8.60% | 0.86% |
ETF's related to CRNX
News
Yahoo
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that company management will participate in three upcoming investment bank conferences. The Piper Sandler 36th Annual Healthcare Conference is being held in New York, NY, and both the Citi Global Healthcare Conferenc
Finnhub
Crinetics management will participate in a fireside chat at the 2024 Citi Global Healthcare Conference on Wednesday, December 4, 2024. Attachments Original document ...
Finnhub
Crinetics management will participate in a fireside chat at the 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024. Attachments Original...
Finnhub
Crinetics management will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024. Attachments Original document ...
Finnhub
Crinetics management participated in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 18, 2024. Attachments Original document ...
Yahoo
Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025 Data From Phase 2 Trial of Paltusotine in Carcinoid Syndrome to be Highlighted in Crinetics Symposium and Two Presentations SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced two abstracts from its transformative, in-house discovery and development
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.